Merck & Co., Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Merck & Co., Inc. trades at $148.25 (market cap $366.28B), while Direxion Daily S&P 500 Bull 3X Shares trades at $282.27. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals.
| MRK | SPXL | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $301.38 |
52-Week Low | $77.60 | $170.20 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SPXL, a leveraged ETF tracking the S&P 500, trades at $285.5, down 1.67% amid broader market caution. Technical indicators show a neutral overall signal with bullish moving averages, while support sits at $284 and resistance at $289. Recent news highlights market resilience despite geopolitical tensions and high valuations, with the S&P 500 up 13% over six months amid Iran conflicts.
The outlook remains mixed: AI-driven earnings growth supports further gains, but elevated valuations and Fed rate risks pose headwinds. Investors face volatility from oil prices and trade policies, yet long-term index fund strategies are favored by analysts targeting S&P 500 levels near 8,000.
Trailing returns across standard periods
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →